




PHARMACEUTICAL 2023

Oncotelic Therapeutics Inc.
Rank 163 of 446





RealRate

PHARMACEUTICAL 2023

Oncotelic Therapeutics Inc. Rank 163 of 446



The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 142%, being 99% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	303
Cost of Goods Sold	0
Intangible Assets	12,071
Liabilities, Current	16,923
Liabilities, Non-Current	0
Other Assets	23,742
Other Compr. Net Income	0
Other Expenses	4,111
Other Liabilities	0
Other Net Income	14,398
Other Revenues	0
Property and Equipment	0
Research and Development	757
Selling, General and Administrative Expense	4,854

Output Variable	Value in 1000 USD
Assets	36,117
Liabilities	16,923
Expenses	9,722
Revenues	0
Stockholders Equity	19,193
Net Income	4,677
Comprehensive Net Income	4,677
Economic Capital Ratio	142%